Ascletis announces oral and poster presentations on asc47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity at the 32nd european congress on obesity

Hong kong , may 6, 2025 /prnewswire/ -- ascletis pharma inc. (hkex:1672, "ascletis") announces oral and poster presentations on preliminary studies of asc47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd european congress on obesity (eco 2025) in malaga, spain. oral presentation details title: asc47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, demonstrated significant weight loss and preserved muscle in dio mice abstract category/topi c : obesity management and intervention » emerging treatments abstract number: 0254 session: t1 abstract session: novel drugs.
ASC Ratings Summary
ASC Quant Ranking